It’s time for reality to catch up to the promise of machine learning in medicine. This means fully integrating molecular and clinical data for improved patient outcomes - in clinical trials and at the bedside. We are building the engineering layer to enact algorithms into clinical practice.
Get the right intervention, to the right patient, at the right time.
Ritankar founded Dascena while a PhD student at the University of Cambridge at the age of 19 with a mission to enable the promise of machine learning to meaningfully improve patient lives. A broadly trained data scientist, Ritankar oversees the algorithm development R&D efforts at Dascena. Prior to Dascena, Ritankar had a range of scientific experiences at Lawrence Berkeley National Labs, Academia Sinica, and the Oxford Institute for Biomedical Engineering. He has authored over 25 peer-reviewed publications, and was the youngest principal investigator funded by the NIH. Ritankar holds an MSc in biomedical engineering from the University of Oxford as well as degrees in bioengineering and chemical biology from the University of California, Berkeley, where he received the University Medal.
Andrew joins Dascena from Tilray, where he operated as Chief Corporate Development Officer through to the company’s announced sale for $1.4bn. During his time at Tilray, Andrew led the rapid global growth of the business, quadrupling revenue while driving the business to achieve profitability over the course of two years. Previously, Andrew was a Managing Director at Goldman Sachs, where he served as a senior leader within the investment bank’s Global Healthcare Group in New York, as well as Canadian Investment Banking franchise. Over the course of his career at Goldman Sachs, Andrew advised on more than $200 billion in M&A and financing transactions across the healthcare industry.
David is a clinical strategy leader at Dascena focusing on new products, health systems partnerships and research. David joins Dascena from Geisinger where he was the founding chief scientific officer and executive vice president and built one of the largest genomics and precision health programs in the world. Prior to Geisinger, David was a professor of human genetics at Emory University School of Medicine. Earlier in his career, he was a professor and founding chair in the department of human genetics at the University of Chicago’s School of Medicine and Branch Chief, Diagnostic Development Branch at the National Human Genome Research Institute. David is board-certified by the American Board of Medical Genetics and Genomics as a clinical laboratory geneticist and is a highly accomplished researcher authoring over 300 peer-reviewed publications (Google Scholar profile) He did his undergraduate work at Tulane University and completed his Ph.D., in psychology (behavioral genetics) at The University of Texas at Austin.
Jonathan oversees new growth areas for Dascena’s platform. His primary responsibilities encompass setting up new structures for the company in undefined areas including establishing Dascena’s commercial models, and our sales and marketing strategy with health systems and diagnostic companies. Jonathan dropped out of Calvin College where he was pursuing a degree in mechanical engineering to join Dascena, and previously started a social entrepreneurship business in college.
Steve oversees the legal function at Dascena and has over 30 years of experience in the biotech, pharma, and technology industries. Steve was most recently a co-founder and the CEO of Kota Biotherapeutics, a startup incubated at Intellectual Ventures in Bellevue, WA. Prior to Kota, Steve was Vice President, Patent Counsel of the Biomedical Group at Intellectual Ventures. Previously, he was VP, General Counsel and Head of Business Development at Ceptyr, Inc. a biotechnology company. Steve also served as the Managing Counsel for IP and Licensing at Immunex Corp, which was acquired by Amgen. Prior to Immunex, he served as a patent attorney for Hoffman La-Roche.